# Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）

> **NCT07660211** · PHASE1 · RECRUITING · sponsor: **VitsGen Therapeutics Inc.** · enrollment: 10 (estimated)

## Conditions studied

- PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** 177Lu-PSMA-VG01

## Key facts

- **NCT ID:** NCT07660211
- **Lead sponsor:** VitsGen Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-16
- **Primary completion:** 2027-05-06
- **Final completion:** 2029-05-06
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07660211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07660211, "Clinical Evaluation of 177Lu-PSMA-VG01 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer （mCRPC）". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07660211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*